Subscribe to our RSS feeds RSS | Login | Register  
 

MM&M's New Drug Dossier combines promotional insights with clinical information to offer marketers the first complete online resource for newly approved drugs. Each dossier features agency rosters, marketing strategy, recent news coverage, clinical insights from Monthly Prescribing Reference (MPR), market data from IMS Health, physician outlook from the GfK US Healthcare Companies and late-stage pipeline candidates from Adis R&D Insight.

For more information or to subscribe click here »



SAMPLE DOSSIER: Vyvanse

November 21, 2007

Shire's marketing strategy with Vyvanse involves converting patients from category leader Adderall XR over to the new drug, which launched in June after its February approval to treat symptoms of ADHD in children aged 6 to 12.
 

Full Drug Index

Most Recent Approvals

Patanase

June 12, 2008

Alcon, which has staked out a position in treating ocular allergies, hopes Patanase extends the franchise beyond eyes.
 

Omnaris

June 12, 2008

The Omnaris brand of ciclesonide, a nasal spray, follows on the heels of another ciclesonide product that Sepracor launched earlier this year—inhaled corticosteroid Alvesco.
 

Entereg

June 04, 2008

Adolor/GlaxoSmithKline's Entereg finally received approval for post-operative ileus (POI), but safety concerns have put a more lucrative potential indication, opioid-induced bowel dysfunction (OBD), out of reach.
 

Relistor

May 14, 2008

Call it opioid-induced constipation (OIC) or, if you prefer, opioid-induced bowel dysfunction (OBD); the condition that often results in patients who are taking opioids to manage late-stage illness could turn out to be a small but lucrative market.
 

Evamist

May 14, 2008

"You just may find relief in a mist," tout marketers of this hot-flash spray, evoking a tagline they hope will differentiate Evamist among the array of patches, lotion, gels and pills available for the symptoms of menopause.
 

Treximet

May 06, 2008

Treximet combines the active ingredient in GlaxoSmithKline's Imitrex with the NSAID naproxen in a pill designed to target multiple mechanisms of migraine.
 

Cimzia

May 05, 2008

Cimzia, a new treatment for Crohn's disease from UCB, has entered a crowded field but could have a sizeable patient potential despite the competition.
 

Lexiscan

April 23, 2008

Lexiscan represents a new option for patients who need pharmacologic stress agents for myocardial perfusion imaging (MPI) studies.
 

Totect

April 23, 2008

TopoTarget USA 's sales force of 10 specialty reps has been promoting Totect to oncology nurses and physicians since the product's launch last year.
 

Rotarix

April 14, 2008

Rotarix is late to a market dominated by another, but the GlaxoSmithKline vaccine for preventing the rotavirus in infants may have a leg up.
 
 
Popular Tags
Advertising Agency Approval Awards Biotech Business Continuing medical education (CME) Digital Direct marketing Direct to consumer (DTC) FDA Generic Government Legal Marketing & Communications Marketing Research Media Online Over the counter (OTC) Pharmaceutical Professional Promotion Regulatory Sales force Suppliers & Vendors